These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34902368)

  • 21. Development and validation of a prognostic gene expression signature for lower-grade glioma following surgery and adjuvant radiotherapy.
    Qian DC; Marascio JA; Tobillo R; Lorenz JW; McCall NS; Neill SG; Hoang KB; Olson JJ; Eaton BR; Shu HG; Zhong J
    Radiother Oncol; 2022 Oct; 175():93-100. PubMed ID: 35998839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. To treat or not to treat? A retrospective multicenter assessment of survival in patients with IDH-mutant low-grade glioma based on adjuvant treatment.
    Paľa A; Coburger J; Scherer M; Ahmeti H; Roder C; Gessler F; Jungk C; Scheuerle A; Senft C; Tatagiba M; Synowitz M; Wirtz CR; Schmitz B; Unterberg AW
    J Neurosurg; 2020 Aug; 133(2):273-280. PubMed ID: 31323633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.
    Wang J; Huang Y; Zhao F; Chen J; He L; Liu Z; Pei Y; Wei Z; Li R; Ai P; Peng X
    J Neurooncol; 2022 Nov; 160(2):433-443. PubMed ID: 36357822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IDH mutations but not TERTp mutations are associated with seizures in lower-grade gliomas.
    Duan WC; Wang L; Li K; Wang WW; Zhan YB; Zhang FJ; Yu B; Bai YH; Wang YM; Ji YC; Zhou JQ; Liu XZ; Zhang ZY
    Medicine (Baltimore); 2018 Dec; 97(50):e13675. PubMed ID: 30558073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas-A Single-Institution, Nine-Year Data.
    Lasica AB; Jaunmuktane Z; Fersht N; Kirkman MA; Dixon L; Hoskote C; Brandner S; Samandouras G
    World Neurosurg; 2021 Jul; 151():e217-e233. PubMed ID: 33866029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
    Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
    Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations.
    Izquierdo C; Barritault M; Poncet D; Cartalat S; Joubert B; Bruna J; Jouanneau E; Guyotat J; Vasiljevic A; Fenouil T; Berthezène Y; Honnorat J; Meyronet D; Ducray F
    Neurosurgery; 2019 Sep; 85(3):E448-E456. PubMed ID: 30407589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adult IDH wild-type lower-grade gliomas should be further stratified.
    Aibaidula A; Chan AK; Shi Z; Li Y; Zhang R; Yang R; Li KK; Chung NY; Yao Y; Zhou L; Wu J; Chen H; Ng HK
    Neuro Oncol; 2017 Oct; 19(10):1327-1337. PubMed ID: 28575485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial.
    Wang J; Wang Y; He Y; Guan H; He L; Mu X; Peng X
    Trials; 2019 Nov; 20(1):641. PubMed ID: 31752981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
    Li R; Chen W; Mao P; Wang J; Jing J; Sun Q; Wang M; Yu X
    Exp Biol Med (Maywood); 2021 Jan; 246(2):187-196. PubMed ID: 33028081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016.
    Compes P; Tabouret E; Etcheverry A; Colin C; Appay R; Cordier N; Mosser J; Chinot O; Delingette H; Girard N; Dufour H; Metellus P; Figarella-Branger D
    J Neurooncol; 2019 May; 142(3):511-520. PubMed ID: 30756272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of immune phenotype with IDH mutation in diffuse glioma.
    Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
    Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide.
    McTyre E; Lucas JT; Helis C; Farris M; Soike M; Mott R; Laxton AW; Tatter SB; Lesser GJ; Strowd RE; Lo HW; Debinski W; Chan MD
    Am J Clin Oncol; 2018 Aug; 41(8):813-819. PubMed ID: 28301347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort.
    Esteyrie V; Dehais C; Martin E; Carpentier C; Uro-Coste E; Figarella-Branger D; Bronniman C; Pouessel D; Ciron DL; Ducray F; Moyal EC; Network P
    Oncologist; 2021 May; 26(5):e838-e846. PubMed ID: 33524191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design.
    Jaeckle KA; Ballman KV; van den Bent M; Giannini C; Galanis E; Brown PD; Jenkins RB; Cairncross JG; Wick W; Weller M; Aldape KD; Dixon JG; Anderson SK; Cerhan JH; Wefel JS; Klein M; Grossman SA; Schiff D; Raizer JJ; Dhermain F; Nordstrom DG; Flynn PJ; Vogelbaum MA
    Neuro Oncol; 2021 Mar; 23(3):457-467. PubMed ID: 32678879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of high-dose radiotherapy with improved survival in patients with newly diagnosed low-grade gliomas.
    Liu Y; Liu S; Li G; Li Y; Chen L; Feng J; Yang Y; Jiang T; Qiu X
    Cancer; 2022 Mar; 128(5):1085-1092. PubMed ID: 34780673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temozolomide for patients with wild-type isocitrate dehydrogenase (IDH) 1 glioblastoma using propensity score matching.
    Tunthanathip T; Sangkhathat S
    Clin Neurol Neurosurg; 2020 Apr; 191():105712. PubMed ID: 32036239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics and outcomes of elderly patients with diffuse gliomas: a multi-institutional cohort study by Kansai Molecular Diagnosis Network for CNS Tumors.
    Sasaki T; Fukai J; Kodama Y; Hirose T; Okita Y; Moriuchi S; Nonaka M; Tsuyuguchi N; Terakawa Y; Uda T; Tomogane Y; Kinoshita M; Nishida N; Izumoto S; Nakajima Y; Arita H; Ishibashi K; Shofuda T; Kanematsu D; Yoshioka E; Mano M; Fujita K; Uematsu Y; Nakao N; Mori K; Kanemura Y
    J Neurooncol; 2018 Nov; 140(2):329-339. PubMed ID: 30076584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas.
    Park YW; Ahn SS; Park CJ; Han K; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK
    Eur Radiol; 2020 Dec; 30(12):6475-6484. PubMed ID: 32785770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
    Keric N; Krenzlin H; Kalasauskas D; Freyschlag CF; Schnell O; Misch M; von der Brelie C; Gempt J; Krigers A; Wagner A; Lange F; Mielke D; Sommer C; Brockmann MA; Meyer B; Rohde V; Vajkoczy P; Beck J; Thomé C; Ringel F
    J Neurooncol; 2024 Mar; 167(1):133-144. PubMed ID: 38326661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.